Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat

Core Viewpoint - Shares of Agios Pharmaceuticals increased nearly 15% in premarket trading following the FDA's approval for an expanded use of its drug mitapivat, indicating strong investor optimism and potential growth for the company [1] Company Summary - Agios Pharmaceuticals received FDA approval for an expanded indication of mitapivat, which is expected to enhance the drug's market potential and drive revenue growth [1] - The approval is likely to strengthen investor confidence in Agios Pharmaceuticals, as reflected in the significant premarket share price increase [1]